JPRN-jRCT2080222335未知2 期
Phase 2 Study of Ipilimumab in Japanese Subjects with Unresectable or Metastatic Melanoma
Bristol-Myers K.K.0 个研究点目标入组 18 人开始时间: 2013年12月19日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Histologically or cytologically confirmed diagnosis of malignant melanoma
- •Previously-treated or untreated unresectable Stage III or Stage IV melanoma
- •Measurable/evaluable disease per modified World Health Organization (mWHO) criteria, within 28 days of first dose of study drug
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
排除标准
- •Active brain metastases
- •Primary ocular or mucosal melanoma
- •History of or current active autoimmune disease
研究者
相似试验
已完成
2 期
Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma PatientsMelanomaNCT01990859Bristol-Myers Squibb20
已完成
1 期
A Phase 1 Study of Olaratumab in Japanese Patients with Advanced Soft Tissue Sarcoma or Advanced Solid TumorsSolid tumorsJPRN-jRCT2080222784Eli Lilly Japan K.K.
已完成
2 期
Phase II Trial of Apixaban in Japanese Patients with Cancer-Associated Venous Thromboembolismcancer-associated venous thromboemborism (CA-VTE)JPRN-UMIN000028447Kobe University Hospital, Medical Oncology / Hematology62
未知
1 期
Japanese Study of Ipilimumab in Combination With Paclitaxel/CarboplatiJPRN-jRCT2080221195Bristol-Myers K.K.15
已完成
2 期
Japanese phase II study in untreated patients with CD20 positive B-cell non-Hodgkin's lymphoma evaluating safety of 90-minute infusion of rituximab.CD20 positive follicular lymphoma or diffuse large B-cell lymphoma.JPRN-jRCT2080223607ZENYAKU KOGYO CO., LTD.33